October 30, 2007 -- Benda Pharmaceuticals (OTCBB: BPMA) announced that its majority-owned China subsidiary, SiBiono, has established a joint venture with DNAVEC to develop a therapeutic vaccine for HIV/AIDS. The vaccine uses gene therapy. DNAVEC chose SiBiono for the JV because SiBiono had already received approval in China for another gene therapy, the cancer drug Gendicine®. SiBiono, which has exclusive distribution rights for the HIV vaccine in China, will be responsible for conducting all of the work for approval. More details...
